Literature DB >> 16940756

Delivery of RNA interference.

Charles X Li1, Amy Parker, Ellen Menocal, Shuanglin Xiang, Laura Borodyansky, Johannes H Fruehauf.   

Abstract

Over the last few years, RNA Interference (RNAi), a naturally occurring mechanism of gene regulation conserved in plant and mammalian cells, has opened numerous novel opportunities for basic research across the field of biology. While RNAi has helped accelerate discovery and understanding of gene functions, it also has great potential as a therapeutic and potentially prophylactic modality. Challenging diseases failing conventional therapeutics could become treatable by specific silencing of key pathogenic genes. More specifically, therapeutic targets previously deemed "undruggable" by small molecules, are now coming within reach of RNAi based therapy. For RNAi to be effective and elicit gene silencing response, the double-stranded RNA molecules must be delivered to the target cell. Unfortunately, delivery of these RNA duplexes has been challenging, halting rapid development of RNAi-based therapies. In this review we present current advancements in the field of siRNA delivery methods, including the pros and cons of each method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940756     DOI: 10.4161/cc.5.18.3192

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  46 in total

1.  In vivo sustained release of siRNA from solid lipid nanoparticles.

Authors:  Tatsiana Lobovkina; Gunilla B Jacobson; Emilio Gonzalez-Gonzalez; Robyn P Hickerson; Devin Leake; Roger L Kaspar; Christopher H Contag; Richard N Zare
Journal:  ACS Nano       Date:  2011-11-18       Impact factor: 15.881

2.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

3.  Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity.

Authors:  Olivia M Merkel; Meredith A Mintzer; Damiano Librizzi; Olga Samsonova; Tanja Dicke; Brian Sproat; Holger Garn; Peter J Barth; Eric E Simanek; Thomas Kissel
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 4.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

5.  Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.

Authors:  Yan Yang; Zehua Wang; Minfang Li; Shi Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

6.  siRNA as a tool for investigating organogenesis: The pitfalls and the promises.

Authors:  Wen-Chin Lee; Rachel Berry; Peter Hohenstein; Jamie Davies
Journal:  Organogenesis       Date:  2008-07       Impact factor: 2.500

Review 7.  Structural diversity repertoire of gene silencing small interfering RNAs.

Authors:  Chan Il Chang; Helena Andrade Kim; Pooja Dua; Soyoun Kim; Chiang J Li; Dong-ki Lee
Journal:  Nucleic Acid Ther       Date:  2011-06       Impact factor: 5.486

Review 8.  siRNA-based therapeutic approaches for rheumatic diseases.

Authors:  Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 9.  Selective gene silencing by viral delivery of short hairpin RNA.

Authors:  Katja Sliva; Barbara S Schnierle
Journal:  Virol J       Date:  2010-09-21       Impact factor: 4.099

10.  Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo.

Authors:  Sungmun Lee; Stephen C Yang; Chen-Yu Kao; Robert H Pierce; Niren Murthy
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.